SiNtx Technologies Inc (SINT)

[TennisStar]

Theory and statistical modeling went out the door when confirmation of CSC approval wasn't coming until late 4Q2016 or early 1Q2017. You know this is fact as this came directly from the company and you and I have discussed at length off line.

If the company sold prior to CSC approval, it would open the door to dozens of class suits. On the other hand if the company sold now, full well knowing CSC FDA approval isn't coming, management could never generate any type of premium. Additionally management holds next to zero shares so there is no incentive for them to sell.

Boston, Amedica IS NOT a biotech and Amedica DOES NOT have P3 lead cancer trial drug that would garner a premium in an M&A...Amedica is a flowndering medical device company that was only promising because of CSC. Remove CSC and it's the same company that has diluted and reverse split to survive.